(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 5.03% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.36%.
Zoetis's revenue in 2026 is $9,467,000,000.On average, 21 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,221,277,090,000, with the lowest ZTS revenue forecast at $4,071,421,753,305, and the highest ZTS revenue forecast at $4,418,832,857,812. On average, 20 Wall Street analysts forecast ZTS's revenue for 2027 to be $4,422,632,007,193, with the lowest ZTS revenue forecast at $4,212,834,535,820, and the highest ZTS revenue forecast at $4,722,342,680,583.
In 2028, ZTS is forecast to generate $4,632,429,478,566 in revenue, with the lowest revenue forecast at $4,325,120,506,414 and the highest revenue forecast at $5,084,950,382,614.